1. Ceftazidime–avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections;Lagacé-Wiens;Core Evidence,2014
2. In vitro susceptibility to ceftazidime–avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM global surveillance study (2012–2014);deJonge;Antimicrob Agents Chemother,2016
3. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement. CLSI document M100-S25,2015
4. European Committee on Antimicrobial Susceptibility Testing. 2015. Breakpoint tables for interpretation of MICs and zone diameters. Version 5.0. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_5.0_Breakpoint_Table_01.pdf [Accessed September 27, 2016].
5. Allergan. 2016. AVYCAZ (ceftazidime–avibactam) for injection, for intravenous use. Prescribing Information. 2016. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206494s002lbl.pdf. [Accessed September 27, 2016].